about
The role of cardiac magnetic resonance in valvular heart diseaseIschemic Heart Disease: Special Considerations in Cardio-Oncology.Routine cine-CMR for prosthesis-associated mitral regurgitation: a multicenter comparison to echocardiography.The role of cardiac MRI in cardio-oncology.Resolution of myelofibrosis-associated pulmonary arterial hypertension following allogeneic hematopoietic stem cell transplantationMagnetic resonance imaging of a scimitar vein and aortic dissection.Stress-Induced Cardiomyopathy in Cancer Patients."Bringing on the light" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry).Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis.Improved reliability in left ventricular ejection fraction assessment by adopting quantitative methods.Evaluation and Management of Cardiac Tumors.Progressive and Reversible Conduction Disease With Checkpoint Inhibitors.Frequent MUGA testing in a myeloma patient: A case-based ethics discussion.Path to Cardiovascular Multimodality Imaging Subspecialty.Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field.Aspergillus endocarditis of the mitral valve with ventricular myocardial invasion, cerebral vasculitis, and intracranial mycotic aneurysm formation in a patient with hemophagocytic lymphohistiocytosis.Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosisBuilding Bridges in Cardiology and Radiology: Why Collaboration Is the Future of Cardiovascular ImagingPrognostic value of delayed enhancement cardiac magnetic resonance imaging in mitral valve repairComparative Assessment of Mitral Regurgitation Severity by Transthoracic Echocardiography and Cardiac Magnetic Resonance Using an Integrative and Quantitative ApproachCardiac amyloidosisTakotsubo Stress Cardiomyopathy: "Good News" in Cancer Patients?Carcinoid heart diseaseEvolution of echocardiography in subclinical detection of cancer therapy-related cardiac dysfunctionEditorial Commentary: Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicitiesHalloween in the Cath Lab: spider web pericardial effusionAssociation between ibrutinib and mid-cavitary Takotsubo cardiomyopathy: a case report and a review of chemotherapy-induced Takostubo's cardiomyopathyFulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor SorafenibAn update on the management and outcomes of cancer patients with severe aortic stenosisCardiac Interventional Procedures in Cardio-Oncology PatientsCardiovascular manifestations of Erdheim-Chester diseaseCoronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation TherapyIn Search of a Less Invasive Approach to Cardiac Tumor Diagnosis: Multimodality Imaging Assessment and BiopsySafety of Diagnostic and Therapeutic Cardiac Catheterization in Cancer Patients With Acute Coronary Syndrome and Chronic ThrombocytopeniaCarcinoid Heart Disease: a Comprehensive ReviewRefractory radiation-induced coronary artery disease: mapping the path and guiding treatment with optical coherence tomographyTargeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint InhibitorsAcute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USAThe Onco-cardiologist Dilemma: to Implant, to Defer, or to Avoid Transcatheter Aortic Valve Replacement in Cancer Patients with Aortic Stenosis?Applications of Cardiac Computed Tomography in the Cardio-Oncology Population
P50
Q30449017-FA25E46E-F206-49BD-839E-E8754A085EFBQ33441165-CF7A3AF7-E898-46BC-A25F-7726BF426C2DQ37326049-0F2B4E16-30ED-4689-918B-DD8F61887E4DQ38668133-C04B40C1-EE68-47BF-806F-C7D4EBD9DDFAQ42111169-F6F22B78-C1EE-47CF-9ED6-4870C17F236DQ42145542-411F84E6-D102-4BD2-B6C8-523F4725D854Q47667060-C05FEB01-A2C1-4BB4-86B2-F2824A91E048Q49978984-744A3BA5-FB3A-4F4A-802D-A0C41B2C7CA0Q50103844-0EF3C38F-5B99-436C-B3E4-7493022D5059Q51088089-308BE304-56A9-4DAB-AE10-58037E701CAFQ52647441-5DCE3BDC-D8C3-4EDB-86D4-9FF5A08F7CD9Q52758556-CF06275B-F1D4-4510-B1D9-62F27214322BQ54503177-F1357CB0-3074-400E-8765-86AB290DC836Q54704125-A688E541-E592-47B3-9B24-B64C9CDA3CE1Q54941852-7E224E13-43AA-4C18-973D-D04CDC494C23Q55364092-9C7D50F7-AF40-448A-8F4F-BD1F29F36B07Q57299899-11CD2420-ACF3-41D5-97BD-2C7B6F2E1048Q58564589-8B0DE00B-9A57-4405-88B1-102962194E0EQ85347550-755A226E-FD11-40C2-BFA7-2A4938803CE5Q86939934-B1FA9AE1-EDD2-4508-9896-7DF0391595FCQ87029708-A9553A3B-1000-44E1-98BD-18D3B25EEE79Q88248174-9B9FB160-FFD6-4899-9784-D9F48CE4E9F8Q88268880-0BCAC06E-9B70-4F9A-B381-8B67434CAC19Q88637333-DAAF7BB9-8C9F-4897-8DCF-10C69F3AB97FQ89352764-21BC7B80-29DE-4706-B8C0-0CA1DE36E8D8Q90006241-CCA99666-6217-45BE-825D-5D38965F7C52Q90289399-0EDD9165-2E82-4C74-8857-EA4CF6B7ECC7Q90445524-1C977D21-21AA-44BD-A1F9-5B1DC327FAD5Q90485321-370396DC-4A5B-49E2-BDD5-667AB52CF293Q90523103-D14EB895-FE32-4841-A8C6-9CC1B3F81C49Q90656963-CA136224-304D-4334-8D68-9C401E632108Q90719909-A2D5F2CC-1ABC-4A4D-8F41-5B3BF97158A7Q90857307-F3D5755B-9018-4E12-AEA8-C390B4C60D17Q91287104-51FB65A2-DDE6-4A29-9B31-E53D89EBA0B6Q91347220-1D66E556-A01B-41E0-84E5-7D89B2900056Q91542502-3B3079E5-3904-45B4-B9E4-BBAF1459C304Q91591383-1C380762-EAC6-408D-8C0C-325445E39CF0Q91681968-CE508EFB-EC46-4687-90EB-B957B1170ECAQ91728934-ED5B9854-A6CA-4B61-80E6-65B0E318355AQ91772090-DCB82F10-0500-4007-81D2-6A96A5E53478
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Juan Lopez-Mattei
@ast
Juan Lopez-Mattei
@en
Juan Lopez-Mattei
@es
Juan Lopez-Mattei
@nl
Juan Lopez-Mattei
@sl
type
label
Juan Lopez-Mattei
@ast
Juan Lopez-Mattei
@en
Juan Lopez-Mattei
@es
Juan Lopez-Mattei
@nl
Juan Lopez-Mattei
@sl
prefLabel
Juan Lopez-Mattei
@ast
Juan Lopez-Mattei
@en
Juan Lopez-Mattei
@es
Juan Lopez-Mattei
@nl
Juan Lopez-Mattei
@sl
P106
P1153
55786889200
P21
P31
P3835
juan-lopez-mattei
P496
0000-0002-1177-8761